Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,504

Document Document Title
WO/2022/161556A1
The present invention provides compounds of general formula I, wherein n is 1, 2 or 3, R1 is selected from the group -CH3; –OCH3; -Br; -Cl; -F; phenoxy; 1-CH3-phenoxy; 1-OCH3-phenoxy; 2-OCH3-phenoxy; 3-CH3-phenoxy; 3-Cl-phenoxy; 3-C(CH...  
WO/2022/162471A1
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.  
WO/2022/160937A1
The present invention provides an industrial preparation method for a high-optical-purity Rimegepant intermediate. Specifically, the present invention provides a chiral resolution method for an isomer mixture of a compound of formula III...  
WO/2022/152705A1
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.  
WO/2022/145986A1
The present invention relates to a naphthalimide sulfonate derivative, and a photoacid generator and a photoresist composition each comprising same and, more specifically, to a naphthalimide sulfonate derivative compound, and a photoacid...  
WO/2022/136020A1
The invention relates to a group of novel electrochromic compounds. More specifically, it relates to benzazoles and condensed azole compounds substituted with one or several pyridinium rings and the use of these compounds as a variable t...  
WO/2022/127320A1
An application of an intermediate or a preparation method therefor in total synthesis of a morphine derivative. On the basis of a possible biogenic pathway of morphine derivatives, efficient production of morphine derivatives, especially...  
WO/2022/127321A1
The invention relates to the field of medicament synthesis and specifically to a novel intermediate, a preparation method for same, and applications thereof. The structural formula of the novel intermediate of the present application is ...  
WO/2022/106352A1
The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]qu inoline-6,7-diol, their use in the treatment of conditions for which treatment with a dopam...  
WO/2022/109268A1
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...  
WO/2022/099937A1
A lappaconitine derivative, a preparation method therefor, and a use thereof. The derivative is an enantiomer, a diastereomer, a racemate, and a mixture thereof, as well as a pharmaceutically acceptable inorganic or organic salt, a cryst...  
WO/2022/100704A1
The present application relates to the field of electroluminescence, and disclosed are a compound, an organic electroluminescent apparatus and a display device. The structural formula of the compound is represented by formula (I). The or...  
WO/2022/101412A1
Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhib...  
WO/2022/090762A1
The present invention concerns dispiroindenopyridines and dispiroindenopyridazines and derivatives thereof, methods for their preparation, the study and definition of their properties, and their uses. In particular, the present invention...  
WO/2022/090514A1
The present invention relates to an active light-emitting layer composition comprising a TADF molecule with TADF properties as a host material and a luminescent molecule with CP properties as a dopant. It also relates to a light-emitting...  
WO/2022/089406A1
A nitrogen-containing fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided are a nitrogen-containing fused heterocyclic compound as shown in formula I, a stereoisomer, a tautomer, or a pharmaceutic...  
WO/2022/078945A1
The invention relates to a process for preparing optically active 2-aryl substituted 6,7-dihydro-5H- cyclopenta[b]pyridin-7-ols comprising asymmetric transfer hydrogenation of the corresponding ketones in presence of a ruthenium catalyst...  
WO/2022/073445A1
Provided is a fused ring diimide derivative having a chemical structure as represented by formula I. Further provided is a preparation method therefor. The fused ring diimide derivative has excellent anti-tumor activity, and the anti-pro...  
WO/2022/063784A1
Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods fo...  
WO/2022/067114A1
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...  
WO/2022/053704A1
The present invention relates to novel candidates for treating viral infections such as HIV, Epstein Barr virus, HPV (Papillomavirus), SARS coronavirus, Ebola virus, Marburg virus, Zika, Herpes (HHV), Hepatitis B, Hepatitis C, Kaposi's s...  
WO/2022/051596A1
The present disclosure relates to compounds of Formula (I') and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...  
WO/2022/040747A1
The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron. In particular embodiments, the compounds are compounds of formul...  
WO/2022/040002A1
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...  
WO/2022/022612A1
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.  
WO/2022/023572A2
Provided are a compound of Formula I or Formula IA, a composition comprising a compound of Formula I or Formula IA, uses of the compounds and compositions to modulate insect behaviour and methods for modulating insect behaviour. Also pro...  
WO/2022/026500A1
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...  
WO/2022/026548A1
Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Ροlθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by...  
WO/2022/018679A1
The present disclosure discloses a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof and a process of preparation of comp...  
WO/2022/013408A2
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...  
WO/2022/008784A1
Use of simple acyclic polyamines for the treatment of parasites of the family Trypanosomatidae. The present invention provides the use of certain simple acyclic polyamines of Formula (I), attached to heterocycles, for the treatment of le...  
WO/2021/255607A1
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use di...  
WO/2021/233428A1
A nitrogen-containing saturated heterocyclic compound having the structure of formula (I) and a preparation method therefor, a pharmaceutical composition, and an application. The nitrogen-containing saturated heterocyclic compound is a s...  
WO/2021/235392A1
The present invention relates to an anti-SARS-CoV-2 drug including, as an active ingredient, a compound represented by formula (I): [wherein R1 is C1-C8 alkyl or the like; and R2-R9 is hydrogen, halogen, hydroxyl, or Q-(C1-C8 alkyl) (Q i...  
WO/2021/228216A1
The present invention relates to a compound of formula (I), and a stereisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, a pharmaceutical composition comprising the compound, a method...  
WO/2021/226276A2
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...  
WO/2021/218755A1
The present invention relates to a compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, a pharmaceutical composition thereof, a preparation method therefor...  
WO/2021/218752A1
Provided herein are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.  
WO/2021/209689A1
A composition comprising a compound or a salt thereof is disclosed. A method for treating a plant curatively and/or preventively against at least one plant pathogenic virus and/or against sweet potato virus disease (SPVD), as well as use...  
WO/2021/195183A1
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...  
WO/2021/191062A1
The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula...  
WO/2021/180081A1
Provided is a compound having the structure represented by formula (I), or a stereoisomer, N-oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. Further provided are a pharmaceutical composition comprising th...  
WO/2021/150700A1
A genus of N-substituted-3-tricyclyl piperidine derivatives is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, ex...  
WO/2021/150806A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical...  
WO/2021/150697A1
A genus of N-substituted-3-tricyclyl piperidine derivatives is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, ex...  
WO/2021/143885A1
A fused tetracyclic compound and an application thereof in a medicine, and in particular, an application of the fused tetracyclic compound as a medicine for treating and/or preventing hepatitis B. Specifically, the invention relates to a...  
WO/2021/142065A1
This disclosure provides a cridin-9-yl-amine, quinolin-9-yl-amine, 1- amino-9H-thioxanthene-9-one and benzo[b][l,5]naphthyridin-10- yl-amine derivatives and structurally related compounds for use as autophagy inhibitors for treating canc...  
WO/2021/130257A1
The present invention relates to dihydro‐cyclopenta‐isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergi...  
WO/2021/131697A1
A purpose of the present invention is to provide a metal complex useful for producing a luminescent element exhibiting an improved luminance life, and the other purpose is to provide a composition containing the metal complex and a lumin...  
WO/2021/130260A1
The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as al...  

Matches 1 - 50 out of 4,504